Estrogen treatment in combination with pyruvate kinase M2 inhibition precipitate significant cumulative antitumor effects in colorectal cancer
Journal of Biochemical and Molecular Toxicology · 2024
DOI: 10.1002/jbt.23799 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biochemical and Molecular Toxicology, 2024. Verfasst von Batoul Abi Zamer und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic Medical Sciences, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates. Hauptthemen laut MEDLINE: Colorectal Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: King Hussein Cancer Foundation, Jordan, Research Institute of Medical and Health Sciences, University of Sharjah, 22010901118.
Abstract (Originalsprache)
It is well established that pyruvate kinase M2 (PKM2) activity contributes to metabolic reprogramming in various cancers, including colorectal cancer (CRC). Estrogen or 17β‐estradiol (E2) signaling is also known to modulate glycolysis markers in cancer cells. However, whether the inhibition of PKM2 combined with E2 treatment could adversely affect glucose metabolism in CRC cells remains to be investigated. First, we confirmed the metabolic plasticity of CRC cells under varying environmental conditions. Next, we identified glycolysis markers that were upregulated in CRC patients and assessed in vitro mRNA levels following E2 treatment. We found that PKM2 expression, which is highly upregulated in CRC clinical samples, is not altered by E2 treatment in CRC cells. In this study, glucose uptake, generation of reactive oxygen species (ROS), lactate production, cell viability, and apoptosis were evaluated in CRC cells following E2 treatment, PKM2 silencing, or a combination of both. Compared to individual treatments, combination therapy resulted in a significant reduction in cell viability and enhanced apoptosis. Glucose uptake and ROS production were markedly reduced in PKM2‐silenced E2‐treated cells. The data presented here suggest that E2 signaling combined with PKM2 inhibition cumulatively targets glucose metabolism in a manner that negatively impacts CRC cell growth. These findings hold promise for novel therapeutic strategies targeting altered metabolic pathways in CRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Basic Medical Sciences, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.
- Research, Institute of Medical and Health Sciences, University of Sharjah, Sharjah, United Arab Emirates.
- Department of Environmental Health, School of Medical Sciences, University of Fukui, Fukui, Japan.
- Department of Medical Laboratory Sciences, College of Health Sciences, University of Sharjah, Sharjah, United Arab Emirates.
- Department of Biomedical Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK.
Förderung
- King Hussein Cancer Foundation, Jordan
- Research Institute of Medical and Health Sciences, University of Sharjah
- 22010901118
Zitieren
APA
Zamer, B. A., Cui, Z. G., Eladl, M. A., Hamad, M., & Muhammad, J. S. (2024). Estrogen treatment in combination with pyruvate kinase M2 inhibition precipitate significant cumulative antitumor effects in colorectal cancer. Journal of Biochemical and Molecular Toxicology. https://doi.org/10.1002/jbt.23799
Vancouver
Zamer BA, Cui ZG, Eladl MA, Hamad M, Muhammad JS. Estrogen treatment in combination with pyruvate kinase M2 inhibition precipitate significant cumulative antitumor effects in colorectal cancer. Journal of Biochemical and Molecular Toxicology. 2024. doi:10.1002/jbt.23799
BibTeX
@article{Zamer2024,
author = {Zamer, Batoul Abi and Cui, Zheng-Guo and Eladl, Mohamed Ahmed and Hamad, Mawieh and Muhammad, Jibran Sualeh},
title = {Estrogen treatment in combination with pyruvate kinase M2 inhibition precipitate significant cumulative antitumor effects in colorectal cancer},
journal = {Journal of Biochemical and Molecular Toxicology},
year = {2024},
doi = {10.1002/jbt.23799}
}
EUVIMED